Quanterix Corporation (QTRX)
NASDAQ (NMS) NASDAQ (NMS) Primary 
Quanterix Corporation (QTRX) Q3 2024 Earnings Conference Call Transcript
Quanterix Corporation (NASDAQ:QTRX ) Q3 2024 Earnings Conference Call November 12, 2024 4:30 PM ET Company Participants Vandana Sriram - CFO Masoud Toloue - President and CEO Conference Call Participants Jake Allen - Goldman Sachs Sung Ji Nam - Scotiabank Kyle Mikson - Canaccord Genuity Puneet Souda - Leerink Partners Thomas DeBourcy - Nephron Research Operator Thank you for standing by. My name is Andrea and I will be your conference operator today.
Quanterix Corporation: Still Struggling To Gain Traction
Today, we revisit Quanterix Corporation, which provides ultra-sensitive digital assay platforms for detecting protein biomarkers in healthcare. The company has a pristine balance sheet with some $300 million in net cash on it. Quanterix Corporation is also seeing steady revenue growth. Unfortunately, the firm is making little progress on the profitability front but is pushing further into early Alzheimer's detection.
Quanterix Corporation (QTRX) Reports Q2 Loss, Tops Revenue Estimates
Quanterix Corporation (QTRX) came out with a quarterly loss of $0.25 per share versus the Zacks Consensus Estimate of a loss of $0.23. This compares to loss of $0.16 per share a year ago.
Analysts Estimate Quanterix Corporation (QTRX) to Report a Decline in Earnings: What to Look Out for
Quanterix (QTRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
